Pfizer Inc. $PFE Stock Holdings Increased by Czech National Bank

Key Points

• Czech National Bank increased its stake in Pfizer by 3.8% in Q4, buying an additional 55,224 shares to hold 1,499,235 shares worth about $37.33 million.
• Analysts are mixed but cautious: the consensus rating is “Hold” with an average price target of $28.19 (breakdown: 1 Strong Buy, 6 Buy, 13 Hold, 3 Sell), though some firms and recent positive oncology readouts have pushed higher targets (examples cited near $36).
• Pfizer beat Q4 estimates with EPS of $0.66 (vs. $0.57 est.) and revenue of $17.56B (vs. $16.93B), and the stock trades around $27.29 (52‑week range $20.92–$27.94) with a market cap of ~$155.2 billion.

Czech National Bank raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,499,235 shares of the biopharmaceutical company's stock after buying an additional 55,224 shares during the quarter. Czech National Bank's holdings in Pfizer were worth $37,331,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of PFE. State Street Corp increased its holdings in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock valued at $7,620,747,000 after acquiring an additional 2,786,098 shares during the last quarter. Norges Bank bought a new position in Pfizer during the second quarter worth $2,270,157,000. Northern Trust Corp boosted its holdings in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC increased its stake in Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock valued at $1,255,860,000 after purchasing an additional 897,786 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock valued at $1,063,565,000 after purchasing an additional 3,296,415 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Royal Bank Of Canada started coverage on shares of Pfizer in a research report on Tuesday, February 24th. They issued an "underperform" rating and a $25.00 price target on the stock. BMO Capital Markets reiterated an "outperform" rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a "neutral" rating on the stock in a research report on Monday, December 15th. TD Cowen restated a "hold" rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $28.19.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline for TALAPRO-3 (TALZENNA + XTANDI) in homologous recombination repair prostate cancer — strengthens Pfizer’s oncology franchise and supports future revenue and labeling opportunities. Pfizer Announces Positive TALAPRO-3 Results
• Positive Sentiment: Guggenheim raised its price target to $36 and upgraded to a buy — a high-profile analyst lift that can drive demand and re-rate the stock if others follow. Benzinga: Guggenheim Raises Price Target
• Positive Sentiment: Analyst and media bullishness on upside from a key prostate‑cancer trial — several write-ups project significant appreciation (examples cite targets near $36) if oncology readouts continue to progress. 247WallSt: Pfizer Could Hit $36
• Positive Sentiment: Coverage highlighting Pfizer as a high‑yield, undervalued play with pipeline catalysts — these narratives attract income and value buyers while emphasizing long‑term upside from new assets. 24/7 Wall St: 6.5% Yielding Dividend Payer
• Positive Sentiment: Pfizer CFO discussed recent oncology milestones on NYSE Live — management visibility on progress helps reduce execution uncertainty and supports investor confidence. Yahoo Finance: CFO Highlights Oncology Milestones
• Neutral Sentiment: Company scheduled a public webcast and analyst call for May 5 to discuss Q1 results and the Q1 performance report — provides a near-term event for updated guidance and pipeline commentary. Yahoo Finance: May 5 Webcast
• Negative Sentiment: Lyme vaccine readout shows ~73% efficacy but missed the trial’s primary statistical target due to low case numbers — clinical/regulatory uncertainty remains and could delay approvals or reduce near-term impact. Yahoo Finance: Pfizer Lyme Vaccine Data
• Negative Sentiment: Competitor momentum: Bristol Myers’ Opdivo label expansions intensify IO competition — pricing and market-share pressure in oncology could constrain long‑term upside for some Pfizer programs. Yahoo Finance: BMY Opdivo Expansion
• Negative Sentiment: Valneva’s stock plunge after mixed Lyme results highlights partner/regulatory risk — market volatility in related vaccine news can spill over to Pfizer sentiment. Yahoo Finance: VALN Mixed Results

Pfizer Price Performance

NYSE PFE opened at $27.29 on Thursday. The company has a 50-day moving average price of $26.78 and a two-hundred day moving average price of $25.65. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The stock has a market cap of $155.16 billion, a price-to-earnings ratio of 20.06 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analysts' expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.